-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: PUBLIC BIOTECH – Stats
Effective Tax Rates for Biotech
The New York Times published a misleading article and companion blog post on corporate tax rates last Thursday, leaving us scratching our heads over the claim that the biotech sector pays a paltry “effective” corporate tax rate of 4.46%, the lowest rate amongst the 20 industries surveyed. After careful reading of the article and examination of supporting documents, we found that the authors vastly underestimated the industry’s effective tax rate. First, the authors incorrectly average Read More >
2010 Biotech Stock Performance
How did biotech stocks perform in 2010? It was a good year for the two most closely followed biotech stock indices, the NBI and BTK, as each outperformed the S&P 500 in 2010. However, in terms of breadth, only 49% of companies posted a gain for 2010 as seen in the first chart below. The 92 companies that started the year in the valuation range of $1M-$50M had a median return of -8%, a reversal Read More >
IPO UPDATE – JANUARY 4th, 2011
In 2010 we saw the return of the Biotech IPO. In the US, 17 biotech companies went public, up from 3 in 2009, and only 1 in 2008. However, almost all of them had to accept a lower price than was sought in the initial filing. The average downward adjustment to the amount raised was 25%. The median and mean amount raised in the US in 2010 was $53M and $84M, respectively. Since the IPO Read More >
How Profitable is the Biotech Drug Development Sector?
Q: How many public biotechnology companies focused on pursuing drug development are profitable? A: Less than 10% Of 225 public biotech companies in the drug development business, only 17 are profitable (7.5%) based on 2009 Net Income. The profitable companies tend to be those with three or more products: Only 1.3% have 1 product AND are profitable (3 of 225) Only 0.9% have 2 products AND make a profit (2 of 225) Only 5.3% have Read More >
Clinical Trial Success Rates – Recent Study from Tufts
Joseph DiMasi and his team at Tufts University published a paper earlier this year in Nature’s Clinical Pharmacology & Therapeutics journal that contains some interesting data on clinical trial success rates. The published data are relevant to biotech investors and business development professionals in that published industry data for clinical outcomes can make a significant difference on the overall valuation of a company. These probabilities can also have a meaningful impact on the ability to Read More >
